CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma

Pigment Cell and Melanoma Research

Volumn 21, Issue 6, 2008, Pages 700-709

  Pastorino, L ^a   Bonelli, L ^b   Ghiorzo, P ^a   Queirolo, P ^b   Battistuzzi, L ^a   Balleari, E ^c   Nasti, S ^a   Gargiulo, S ^a   Gliori, S ^b   Savoia, P ^d   Abate Osella, S ^d   Bernengo, M G ^d   Bianchi Scarra G ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

CDKN2A; Familial melanoma; Germline mutations; MC1R; Multiple melanoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATION RATE; PRIMARY TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC VARIATION; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; RECEPTOR, MELANOCORTIN, TYPE 1; RISK FACTORS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 56249147495     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00512.x     Document Type: Article

References (47)

1. Bartsch, D.K., Sina-Frey, M., Lang, S., et al. (2002). CDKN2A germline mutations in familial pancreatic cancer. Ann Surg. 236, 730 737.
2. Beaumont, K.A., Shekar, S.N., Newton, R.A., James, M.R., Stow, J.L., Duffy, D.L. Sturm, R.A. (2007). Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum. Mol. Genet. 16, 2249 2260.
3. Berwick, M., Orlow, I., Hummer, A.J. et al. (2006). The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol. Biomarkers Prev. 15, 1520 1555.
4. Box, N.F., Duffy, D.L., Chen, W., Stark, M., Martin, N.G., Sturm, R.A. Hayward, N.K. (2001). MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am. J. Hum. Genet. 69, 765 773.
5. Chaudru, V., Laud, K., Avril, M.F., Minière, A., Chompret, A., Bressac-de Paillerets, B. Demenais, F. (2005). Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol. Biomarkers Prev. 14, 2384 2390.
6. Della Torre, G., Pasini, B., Frigerio, S. et al. (2001). CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br. J. Cancer 85, 836 844.
7. Dodd, A.T., Morelli, J., Mokrohisky, S.T., Asdigian, N., Byers, T.E. Crane, L.A. (2007). Melanocytic nevi and sun exposure in a cohort of colorado children: anatomic distribution and site-specific sunburn. Cancer Epidemiol. Biomarkers Prev. 16, 2136 2143.
8. Eliason, M.J., Larson, A.A., Florell, S.R., Zone, J.J., Cannon-Albright, L.A., Samlowski, W.E. Leachman, S.A. (2006). Population-based prevalence of CDKN2A mutations in Utah melanoma families. J. Invest. Dermatol. 126, 660 666.
9. Ferrone, C.R., Ben Porat, L., Panageas, K.S., Berwick, M., Halpern, A.C., Patel, A. Coit, D.G. (2005). Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 294, 1647 1654.
10. Flanagan, N., Healy, E., Ray, A., Philips, S., Todd, C., Jackson, I.J., Birch-Machin, M.A. Rees, J.L. (2000). Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum. Mol. Genet. 9, 2531 2537.
11. García-Borrón, J.C., Sánchez-Laorden, B.L. Jiménez-Cervantes, C. (2005). Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res. 18, 393 410.
12. Ghiorzo, P., Ciotti, P., Mantelli, M., et al. (1999). Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int. J. Cancer. 83, 441 448.
13. Ghiorzo, P., Gargiulo, S., Pastorino, L. et al. (2006). Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Hum. Mol. Genet. 15, 2682 2689.
14. Goldstein, A.M., Landi, M.T., Tsang, S., Fraser, M.C., Munroe, D.J. Tucker, M.A. (2005). Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol. Biomarkers Prev. 14, 2208 2212.
15. Goldstein, A.M., Chan, M., Harland, M. et al. (2006). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 66, 9818 9828.
16. Goldstein, A.M., Chaudru, V., Ghiorzo, P. et al. (2007). Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int. J. Cancer 121, 825 831.
17. Hashemi, J., Platz, A., Ueno, T., Stierner, U., Ringborg, U. Hansson, J. (2000). CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res. 60, 6864 6867.
18. Helsing, P., Nymoen, D.A., Ariansen, S. et al. (2008). Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 47, 175 184.
19. Holland, E.A., Schmid, H., Kefford, R.F. Mann, G.J. (1999). CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 25, 339 348.
20. Hussussian, C.J., Struewing, J.P., Goldstein, A.M., Higgins, P.A., Ally, D.S., Sheahan, M.D., Clark, W.H., Jr., Tucker, M.A. Dracopoli, N.C. (1994). Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15 21.
21. Jiménez-Cervantes, C., Germer, S., González, P., Sánchez, J., Sánchez, C.O. García-Borrón, J.C. (2001). Thr40 and Met122 are new partial loss-of-function natural mutations of the human melanocortin 1 receptor. FEBS Lett. 508, 44 48.
22. John, P.R. Ramsay, M. (2002). Four novel variants in MC1R in red-haired South African individuals of European descent: S83P, Y152X, A171D, P256S. Hum. Mutat. 19, 461 462.
23. Kanetsky, P.A., Ge, F., Najarian, D., Swoyer, J., Panossian, S., Schuchter, L., Holmes, R., Guerry, D. Rebbeck, T.R. (2004). Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach. Cancer Epidemiol. Biomarkers Prev. 13, 808 819.
24. Kanetsky, P.A., Rebbeck, T.R., Hummer, A.J. et al. (2006). Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res. 66, 9330 9337.
25. Kefford, R.F., Newton Bishop, J.A., Bergman, W. Tucker, M.A. (1999). Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J. Clin. Oncol. 10, 3245 3251.
26. Lynch, H.T., Brand, R.E., Hogg, D. et al. (2002). Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94, 84 96.
27. Majore, S., De Simone, P., Crisi, A., Eibenschutz, L., Binni, F., Antigoni, I., De Bernardo, C., Catricalà, C. Grammatico, P. (2008). CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma. Pigment Cell Melanoma Res. 21, 209 211.
28. Mantelli, M., Barile, M., Ciotti, P. et al. (2002). High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am. J. Med. Genet. 107, 214 221.
29. Mantelli, M., Pastorino, L., Ghiorzo, P. et al. (2004). Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Res. 14, 443 448.
30. Molven, A., Grimstvedt, M.B., Steine, S.J., Harland, M., Avril, M.F., Hayward, N.K. Akslen, L.A. (2005). A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 44, 10 18.
31. Norusis, M.J. (1989-2007). SPSS 16.0, release 16.0.1. Chicago : SPSS Inc.
32. Pastorino, L., Cusano, R., Bruno, W., Lantieri, F., Origone, P., Barile, M., Gliori, S., Shepherd, G.A., Sturm, R.A. Bianchi-Scarrà, G. (2004). Novel MC1R variants in Ligurian melanoma patients and controls. Hum. Mutat. 24, 103.
33. Pjanova, D., Engele, L., Randerson-Moor, J.A. et al. (2007). CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res. 17, 185 191.
34. Pollock, P.M., Yu, F., Qiu, L., Parsons, P.G. Hayward, N.K. (1995). Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene 11, 663 668.
35. Puig, S., Malvehy, J., Badenas, C. et al. (2005). Role of the CDKN2A locus in patients with multiple primary melanomas. J. Clin. Oncol. 23, 3043 3051.
36. Qanbar, R. Bouvier, M. (2003). Role of palmitoylation/depalmitoylation reactions in G-protein-coupled receptor function. Pharmacol. Ther. 97, 1 33.
37. Schlesselman, J.J. (1982). Case-Control Studies. Design, Conduct, Analysis New York : Oxford University Press).
38. Sharpless, N.E. DePinho, R.A. (1999). The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9, 22 30.
39. de Snoo, F.A. Hayward, N.K. (2005). Cutaneous melanoma susceptibility and progression genes. Cancer Lett. 230, 153 186.
40. Soufir, N., Avril, M.F., Chompret, A., Demenais, F., Bombled, J., Spatz, A., Stoppa-Lyonnet, D., Bénard, J. Bressac-de Paillerets, B. (1998). Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum. Mol. Genet. 7, 209 216.
41. Soufir, N., Lacapere, J.J., Bertrand, G. et al. (2004). Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. Br. J. Cancer 90, 503 509.
42. Soufir, N., Ollivaud, L., Bertrand, G. et al. (2007). A French CDK4-positive melanoma family with a co-inherited EDNRB mutation. J. Dermatol. Sci. 46, 61 64.
43. Sturm, R.A., Duffy, D.L., Box, N.F., Chen, W., Smit, D.J., Brown, D.L., Stow, J.L., Leonard, J.H. Martin, N.G. (2003a). The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res. 16, 266 272.
44. Sturm, R.A., Duffy, D.L., Box, N.F., Newton, R.A., Shepherd, A.G., Chen, W., Marks, L.H., Leonard, J.H. Martin, N.G. (2003b). Genetic association and cellular function of MC1R variant alleles in human pigmentation. Ann. N. Y. Acad. Sci. 994, 348 358.
45. Tucker, M.A. Goldstein, A.M. (2003). Melanoma etiology: where are we? Oncogene 22, 3042 3052.
46. Zhou, X., Tarmin, L., Yin, J., Jiang, H.Y., Suzuki, H., Rhyu, M.G., Abraham, J.M. Meltzer, S.J. (1994). The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9, 3737 3741.
47. Zuo, L., Weger, J., Yang, Q., Goldstein, A.M., Tucker, M.A., Walker, G.J., Hayward, N. Dracopoli, N.C. (1996). Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12, 97 99.